Biotalk
by Biotalk
Latest episode
Biotalk Episode 39: Asia’s 2026 Q3 Report: Global Trends in…
Biotalk Episode 39: Asia’s 2026 Q3 Report: Global Trends in…
About this podcast
Welcome to Biotalk, Locust Walk’s podcast for biotech deal makers and innovators.
Episodes
The newest 20 of 28 episodes
- Biotalk Episode 39: Asia’s 2026 Q3 Report: Global Trends in Biopharma Transactions · 12 minNo megadeals, no retreat: China’s average deal fell to $1.7B, but it still holds 58% of global licensing value. In the Asia-focused Episode 39, Geoff Meyerson, CEO of Locust…
- Biotalk Episode 38: 2026 Q3 Report: Global Trends in Biopharma Transactions · 12 minM&A has already topped all of 2025, and China still holds 58% of global licensing value. In Episode 38 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q3…
- Biotalk Episode 37: Asia’s 2026 Q2 Report: Global Trends in Biopharma Transactions · 9 minDuring the Asia-focused Episode 37 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key trends from the 2026 Q2 Report: Global Trends in Biopharma Transactions, across…
- Biotalk Episode 36: 2026 Q2 Report: Global Trends in Biopharma Transactions · 12 minDuring Episode 36 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q2 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals…
- Biotalk Episode 35: Asia’s 2026 Q1 Report: Global Trends in Biopharma TransactionsDuring the Asia-focused Episode 35 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2026 Q1 trends across China, Japan, and Korea. China: Dominated global licensing…
- Biotalk Episode 34: 2026 Q1 Report: Global Trends in Biopharma Transactions · 5 minDuring Episode 34 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q1 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals…
- Biotalk Episode 33: Asia’s 2025 Year-In-Review Report: Global Trends in Biopharma Transactions · 6 minDuring the Asia-focused Episode 33 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2025 Year-In-Review trends across China, Japan, and Korea. China: Led global…
- Biotalk Episode 32: 2025 Year-In-Review Report: Global Trends in Biopharma Transactions · 11 minDuring Episode 32 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Year-In-Review Report: Global Trends in Biopharma Transactions, covering capital markets…
- Episode 31: Asia’s 2025 Q3 Report: Global Trends in Biopharma Transactions · 5 minDuring Episode 31 of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores Asia-Pacific biotech momentum across China, Japan, and Korea, as featured in our 2025 Q3 Report: Global…
- Biotalk Episode 30: 2025 Q3 Report: Global Trends in Biopharma Transactions · 13 minDuring Episode 30 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q3 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic…
- Episode 29: Asia’s 2025 Q2 Report: Global Trends in Biopharma Transactions · 8 minDuring the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in Japan, China, Korea, Australia, and the…
- Biotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma Transactions · 17 minDuring Episode 28 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q2 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic…
- Episode 27: Inside the Biopharma Market: 2025 Outlook & Emerging Trends · 8 minDuring Episode 27 of Biotalk, Geoff Meyerson, CEO of Locust Walk, steps back to examine the macro forces shaping the biopharma landscape. After holding a bearish outlook since…
- Episode 26: Asia’s 2025 Q1 Report: Global Trends in Biopharma Transactions · 11 minDuring the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, as featured in our 2025 Q1 Report: Global…
- Biotalk Episode 25: 2025 Q1 Report: Global Trends in Biopharma Transactions · 13 minDuring Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic…
- Biotalk Episode 24: Asia's 2024 Year-In-Review · 12 minDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China, highlighting key trends and developments shaping…
- Biotalk Episode 23: 2024 Year-In-Review Report: Global Trends in Biopharma Transactions · 14 minDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the…
- Biotalk Episode 22: A Conversation with Sudhir Agrawal of ARNAY Sciences · 30 minOn this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President of ARNAY Sciences and a pioneer in RNA…
- Biotalk Episode 21: Analyzing the 2024 U.S. Election's Impact on Biotech · 34 minIn this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel Brog, Senior Vice President, for an insightful…
- Biotalk Episode 20: A Conversation with David Harel of CytoReason · 34 minOn this episode of BioTalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to…







